Chromium [51Cr] EDTA Injection GE Healthcare 3.7 MBq/ ml Norwegen - Norwegisch - Statens legemiddelverk

chromium [51cr] edta injection ge healthcare 3.7 mbq/ ml

ge healthcare ltd - krom (51cr) edetat - injeksjonsvæske, oppløsning - 3.7 mbq/ ml

Cefotaxim MIP 2 g Norwegen - Norwegisch - Statens legemiddelverk

cefotaxim mip 2 g

mip pharma gmbh - cefotaksimnatrium - pulver til injeksjons-/infusjonsvæske, oppløsning - 2 g

Cefotaxim MIP 1 g Norwegen - Norwegisch - Statens legemiddelverk

cefotaxim mip 1 g

mip pharma gmbh - cefotaksimnatrium - pulver til injeksjons-/infusjonsvæske, oppløsning - 1 g

Senstend Europäische Union - Norwegisch - EMA (European Medicines Agency)

senstend

plethora pharma solutions limited - lidokain, prilocaine - for tidlig utløsning - anestetika - senstend er angitt for behandling av primær prematur ejakulasjon hos voksne menn.

Nebido 1000 mg/4 ml Norwegen - Norwegisch - Statens legemiddelverk

nebido 1000 mg/4 ml

grünenthal gmbh - testosteronundekanoat - injeksjonsvæske, oppløsning - 1000 mg/4 ml

Ondansetron Kalceks 2 mg/ ml Norwegen - Norwegisch - Statens legemiddelverk

ondansetron kalceks 2 mg/ ml

as kalceks - ondansetronhydrokloriddihydrat - injeksjons-/infusjonsvæske, oppløsning - 2 mg/ ml

Rhophylac 1500 IU/2 ml Norwegen - Norwegisch - Statens legemiddelverk

rhophylac 1500 iu/2 ml

csl behring gmbh - immunglobulin anti-d, humant - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 1500 iu/2 ml

Flumazenil Fresenius Kabi 0.1 mg/ ml Norwegen - Norwegisch - Statens legemiddelverk

flumazenil fresenius kabi 0.1 mg/ ml

fresenius kabi norge as - halden - flumazenil - injeksjonsvæske, oppløsning - 0.1 mg/ ml

Palonosetron Fresenius Kabi 250 mikrog Norwegen - Norwegisch - Statens legemiddelverk

palonosetron fresenius kabi 250 mikrog

fresenius kabi norge as - palonosetronhydroklorid - injeksjonsvæske, oppløsning - 250 mikrog

Comirnaty Europäische Union - Norwegisch - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaksiner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.